Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinuvel PharmaceuticalsCLVLF -0.51%85 Days Sales Outstanding is 54.97 as of Jun. 2026, which is 34% below its 10-year median of 83.92. GuruFocus rates CLVLF with a GF Score™ of 85/100 and a GF Value™ of $9.34 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 841 Biotechnology companies, Clinuvel Pharmaceuticals ranks worse than 55.65% on this metric.
Clinuvel Pharmaceuticals (OTCPK:CLVLF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Clinuvel Pharmaceuticals Days Sales Outstanding Related Terms
Clinuvel Pharmaceuticals Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Clinuvel Pharmaceuticals's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals Days Sales Outstanding Chart
CLVLF vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's Days Sales Outstanding falls into.
Clinuvel Pharmaceuticals Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals (CLVLF) has a Days Sales Outstanding of 54.97 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Clinuvel Pharmaceuticals and its competitors. This is 34% below median its historical median of 83.92. Over the past decade, Clinuvel Pharmaceuticals' Days Sales Outstanding has ranged from 51.12 to 95.15. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #468 out of 841 companies in the Biotechnology industry, placing it in the top 55.6%.
Is Clinuvel Pharmaceuticals' Days Sales Outstanding too high?
Clinuvel Pharmaceuticals' current Days Sales Outstanding of 54.97 is 34% below median its 10-year median of 83.92. Over the past 10 years, this metric has ranged from a low of 51.12 to a high of 95.15. The Biotechnology industry median Days Sales Outstanding is 68.94. Clinuvel Pharmaceuticals' value of 54.97 is 20.3% below this industry median. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #468 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #468 out of 841 companies for Days Sales Outstanding. This places Clinuvel Pharmaceuticals in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. Clinuvel Pharmaceuticals' value of 54.97 is 20.3% below this benchmark. Historically, Clinuvel Pharmaceuticals' own Days Sales Outstanding has ranged from 51.12 to 95.15 over the past decade. While the company's 10-year median is 83.92 vs. the industry median of 68.94, Clinuvel Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinuvel Pharmaceuticals's current Days Sales Outstanding of 54.97 is 20.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Clinuvel Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinuvel Pharmaceuticals's current Days Sales Outstanding is 54.97, which is 34% below median its own 10-year median of 83.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (CLVLF) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.34, compared to a current price of $5.89 — trading 36.9% below its estimated fair value. The current Days Sales Outstanding is 54.97, which is 34% below median its 10-year median of 83.92 and 20.3% below the Biotechnology industry median of 68.94. Clinuvel Pharmaceuticals' overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (CLVLF), the current Days Sales Outstanding is 54.97 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (CLVLF) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of $5.89 is trading 36.9% below its estimated GF Value™ of $9.34.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for CLVLF:
Days Sales Outstanding: 54.97 (34% below median its 10-year median of 83.92)
GF Value™: $9.34 vs. price of $5.89 (36.9% below fair value)
Industry Position: 20.3% below the Biotechnology median (#468 of 841)
No single metric tells the full story. See the CLVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
85GF Score
Get the complete analysis for CLVLF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLVLF has been successfully added to your 
